In evaluating antimicrobial agents with similar spectra of activity, it is difficult to determine equivalent dosage regimens. In vitro potency, pharmacokinetic disposition, and other factors determine the usual dosing regimen. Knowledge of the serum bactericidal activity over time may assist in defining the potency of comparative antimicrobial agents. Cefoxitin and ceftizoxime, cephalosporins with gram-negative aerobic and anaerobic activity, have been promoted as monotherapy in the treatment of intra-abdominal infection. In a randomized, crossover study, six healthy volunteers received single 30-mg/kg doses of cefoxitin and ceftizoxime. Greater serum activity against Escherichia coli and Bacteroides fragilis was observed with ceftizoxime than with cefoxitin. The results suggest that ceftizoxime can be administered in a lower daily dosage than cefoxitin. We propose that the present study may serve as a prototype for future studies attempting to assess equivalent dosing regimens for antibiotics with similar spectra of activity.
A variety of antimicrobial agents have been used as monotherapy in the treatment of mixed aerobic-anaerobic intra-abdominal infection. Cephalosporins such as cefoxitin (4) , cefotetan (2) , and certain broad-spectrum agents such as ceftizoxime (6) and cefotaxime (10) have been found to have a role in this setting. Which agent is best suited for the treatment of intra-abdominal infection is unclear. Considering the similarity of these antibiotics with respect to their antimicrobial spectrum and toxicity, the choice of antibiotic is often based on cost factors. When comparing like antimicrobial agents, it is difficult to determine the equivalence of dosing regimens. Knowledge of the serum bactericidal activity over time may result in a useful method of determining dosage equivalence.
The most common pathogens associated with intra-abdominal sepsis are Bacteroides fragilis and Escherichia coli (11) . Cefoxitin and ceftizoxime have similar activity against B. fragilis, with reported MICs for 90% of strains tested (MIC90s) of 16 to 32 ,ug/ml (3, 5, 8) . Against E. coli, the MIC90 of cefoxitin has been reported to be 2 to 6 ,ug/ml, whereas the MIC90 of ceftizoxime ranges from 0.06 to 0.25 ,ug/ml (3, 5, 8) .
A potential limitation of the use of cefoxitin is its short half-life (0.8 h), necessitating frequent doses in the treatment of infection (9) . Ceftizoxime, with a longer half-life (1.6 h) (8) and increased potency versus gram-negative aerobes, may offer certain advantages over cefoxitin, resulting in the need for lower doses or less frequent administration.
We elected to study the serum bactericidal activity over time of cefoxitin and ceftizoxime. for which the MICs of each antibiotic were similar. For all three anaerobic isolates, the MIC of cefoxitin ranged from 4 to 10 ,ug/ml, and the MIC of ceftizoxime was 3 ,ug/ml. The bactericidal activity of serum samples was determined in triplicate by a microdilution technique that followed guidelines laid down by the National Committee for Clinical Laboratory Standards (7). The serum inhibitory titer (SIT) was defined as the highest dilution that showed no visible turbidity after an 18-to 24-h incubation period at 35°C. A 10-,ul sample from each well showing no visible growth was subcultured onto antibiotic-free blood agar media and incubated at 35°C for 18 to 24 h. From the number of colonies, the volume of sample subcultured, and the size of the initial inoculum, the fraction of the initial inoculum that was killed was calculated. The greatest dilution of a serum sample that killed >99.9% of the initial inoculum was defined as the serum bactericidal titer (SBT) level. An anaerobic chamber was used for incubation of B. fragilis isolates. The MICs and MBCs were similarly determined with standard solutions of antibiotics; supplemented Mueller-Hinton broth replaced serum for the dilution steps.
Pharmacodynamic analysis. The area under the serum bactericidal activity curve (AUBC) (1) for E. coli was calculated by plotting the reciprocal of the SBT against time and applying the trapezoidal rule from 0 to 12 h. A similar analysis was performed for B. fragilis, with serum inhibitory activity plotted against time.
Statistical analysis. The mean AUBC was tested by using the paired t test to determine significant differences (P < 0.05) between the two drugs.
RESULTS
Mean levels of cefoxitin and ceftizoxime in serum are indicated in Table 1 . Concentrations of ceftizoxime were greater than those of cefoxitin at all observed periods. Cefoxitin was noted to have a mean terminal half-life of 0.8 h, whereas ceftizoxime had a corresponding half-life of 1.7 h in the subjects. The mean area under the curve (AUC) was 118. 4 ,ug h/ml for cefoxitin versus 267.3 ,ug-h/ml for ceftizoxime.
The mean serum bactericidal activity values for ceftizoxime and cefoxitin against E. coli are indicated in Table 1 . Cefoxitin had no bactericidal activity after 2 h in any of the aerobic isolates. Inhibitory activity was observed up to 2 to 4 h after the administration of the dose. Conversely, mean SBTs of 1:9, 1:15, and 1:3 (for the three strains) were observed with ceftizoxime 8 h after the dose. Serum inhibitory activity was maintained throughout the 12-h sampling period. Table 2 and Fig. 1 demonstrate the differences between cefoxitin and ceftizoxime when AUBC analysis was used. For each isolate of E. coli, ceftizoxime demonstrated significantly greater bactericidal activity than cefoxitin did (P < 0.05). It is noteworthy that the increased activity of ceftizoxime over that of cefoxitin cannot be explained entirely on the basis of the AUC. A 2-fold difference in AUC and up to a 27-fold difference in AUBC were observed when comparing ceftizoxime with cefoxitin. The increased in vitro potency of ceftizoxime probably accounted for this increase in microbiologic activity as measured by AUBC.
Little bactericidal activity was noted with either cefoxitin or ceftizoxime against B. fragilis (Table 3) . Predictable killing was observed only at peak antibiotic levels with both agents. Although little bactericidal activity was noted, ceftizoxime maintained SITs against all three isolates for 8 h, compared with 4 h for cefoxitin (Table 3 ). Since little bactericidal activity was observed, we elected to plot the SIT versus time to compare the relative anaerobic activity of the antibiotics (Table 4 ; Fig. 2 ). The area under the inhibitory titer curve (AUIC) was similar for both antibiotics against strain ATCC 25285. However, greater inhibitory activity was observed with ceftizoxime than with cefoxitin against the clinical isolates of B. fragilis. However, the difference between these agents did not achieve statistical significance.
DISCUSSION
The choice of antibiotic in the monotherapy treatment of intra-abdominal infection is controversial. Microbiologic ac- tivity, clinical experience, safety, and cost are important considerations in the selection of the antibiotic. When comparing antibiotics which have similar spectra of activity and safety profiles, cost differential becomes a major determinant in the selection of therapy. It is possible that the use of an antimicrobial agent with a longer half-life and/or greater in vitro potency will result in more cost-effective therapy, because of the less-frequent administration and lower daily doses required. However, it is difficult to determine equal dosing regimens when comparing antibiotics with similar antibacterial spectra. In an attempt to compare the potency of cefoxitin and ceftizoxime, we elected to study the serum bactericidal and serum inhibitory activity of the drugs over time. Our results demonstrated that equal doses of these drugs resulted in significantly greater bactericidal activity of ceftizoxime than of cefoxitin against all three isolates of E. coli. The AUBC for ceftizoxime was 1.5 to 27 times that for cefoxitin (Table 2) . Furthermore, no bactericidal activity was noted after 2 h in any of the isolates when cefoxitin was 
